Quantitation of transient XXXX by digital, ambulatory electrocardiography.

@entity1 @entity308 @entity583 @entity63 @entity1242 @entity951 @entity741 @entity453
Transient @entity741 is more frequently silent than accompanied by @entity951 . The frequency of @entity63 varies markedly from day to day, so that in order to accurately define the total @entity63 burden, it may be necessary to quantitate @entity63 episodes for periods longer than 24 hours. Therefore, a programmable, digital device was developed for long-term, interactive, ambulatory monitoring of the electrocardiogram, which uses variations in a time-averaged ST level as an indicator of @entity741 . The electrocardiographic signal is digitized at 256 Hz and analyzed by an algorithm. If @entity308 is planar or downsloping and persists for more than 40 seconds, and if the @entity308 is equal to or more than a user-programmed threshold, the device marks the onset of an @entity63 event and times it. The algorithm has been validated by comparison of its analysis of the ST segment to @entity1 and computerized analyses of frequency-modulated Holter recordings and stress tests. To assess the feasibility and utility of long-term monitoring, @entity1 with documented @entity453 were monitored continuously for 14-day periods. Of 26 @entity1 enrolled, 8 completed a protocol for individualization of anti- @entity63 therapy using transdermal @entity1242 . Over 90% of @entity63 episodes in this group of @entity1 , all of whom had had a previous @entity583 , were silent. Treatment with 10 mg of transdermal @entity1242 reduced the number of @entity63 episodes by 59% and the duration of @entity63 by 60% (p less than 0.001); there was no diminution in the effectiveness of treatment from week 1 to week 2.(ABSTRACT TRUNCATED AT 250 WORDS)
